image
Healthcare - Medical - Instruments & Supplies - NASDAQ - US
$ 1.63
-1.21 %
$ 80.8 M
Market Cap
-1.41
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Mar, 2, 2025.

The intrinsic value of one AKYA stock under the worst case scenario is HIDDEN Compared to the current market price of 1.63 USD, Akoya Biosciences, Inc. is HIDDEN

This DCF valuation model was last updated on Mar, 2, 2025.

The intrinsic value of one AKYA stock under the base case scenario is HIDDEN Compared to the current market price of 1.63 USD, Akoya Biosciences, Inc. is HIDDEN

This DCF valuation model was last updated on Mar, 2, 2025.

The intrinsic value of one AKYA stock under the best case scenario is HIDDEN Compared to the current market price of 1.63 USD, Akoya Biosciences, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
96.6 M REVENUE
29.09%
-57.7 M OPERATING INCOME
12.90%
-63.3 M NET INCOME
10.36%
-50.9 M OPERATING CASH FLOW
4.85%
3.35 M INVESTING CASH FLOW
123.77%
56.8 M FINANCING CASH FLOW
97.88%
18.8 M REVENUE
-18.78%
-8.35 M OPERATING INCOME
24.68%
-10.5 M NET INCOME
19.90%
-9.26 M OPERATING CASH FLOW
16.17%
13 M INVESTING CASH FLOW
43.79%
-150 K FINANCING CASH FLOW
92.94%
Balance Sheet Akoya Biosciences, Inc.
image
Current Assets 122 M
Cash & Short-Term Investments 83.1 M
Receivables 17 M
Other Current Assets 21.7 M
Non-Current Assets 58.6 M
Long-Term Investments 0
PP&E 20.7 M
Other Non-Current Assets 37.9 M
Current Liabilities 35.3 M
Accounts Payable 11.8 M
Short-Term Debt 3.45 M
Other Current Liabilities 20.1 M
Non-Current Liabilities 91.3 M
Long-Term Debt 82.3 M
Other Non-Current Liabilities 9 M
EFFICIENCY
Earnings Waterfall Akoya Biosciences, Inc.
image
Revenue 96.6 M
Cost Of Revenue 40.3 M
Gross Profit 56.3 M
Operating Expenses 114 M
Operating Income -57.7 M
Other Expenses 5.66 M
Net Income -63.3 M
RATIOS
58.27% GROSS MARGIN
58.27%
-59.68% OPERATING MARGIN
-59.68%
-65.53% NET MARGIN
-65.53%
-117.77% ROE
-117.77%
-35.11% ROA
-35.11%
-38.87% ROIC
-38.87%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Akoya Biosciences, Inc.
image
Net Income -63.3 M
Depreciation & Amortization 8.89 M
Capital Expenditures -3.65 M
Stock-Based Compensation 10.4 M
Change in Working Capital -14.5 M
Others 5.6 M
Free Cash Flow -54.6 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Akoya Biosciences, Inc.
image
Wall Street analysts predict an average 1-year price target for AKYA of $5.08 , with forecasts ranging from a low of $3 to a high of $7.5 .
AKYA Lowest Price Target Wall Street Target
3 USD 84.05%
AKYA Average Price Target Wall Street Target
5.08 USD 211.86%
AKYA Highest Price Target Wall Street Target
7.5 USD 360.12%
4. DIVIDEND ANALYSIS
5. COMPETITION
6. Ownership
Insider Ownership Akoya Biosciences, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
30.7 K USD 1
9-12 MONTHS
111 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
8 months ago
Jun 11, 2024
Sell 15.6 K USD
McKelligon Brian
President and CEO
- 7500
2.084 USD
8 months ago
Jun 06, 2024
Sell 15.1 K USD
McKelligon Brian
President and CEO
- 7500
2.0085 USD
11 months ago
Mar 20, 2024
Sell 37.2 K USD
McKelligon Brian
President and CEO
- 7500
4.9657 USD
11 months ago
Mar 13, 2024
Sell 37 K USD
McKelligon Brian
President and CEO
- 7500
4.939 USD
11 months ago
Mar 13, 2024
Sell 37 K USD
McKelligon Brian
President and CEO
- 7500
4.938 USD
1 year ago
Dec 19, 2023
Sell 33.6 K USD
McKelligon Brian
President and CEO
- 7500
4.4754 USD
1 year ago
Dec 12, 2023
Sell 31.9 K USD
McKelligon Brian
President and CEO
- 7500
4.2495 USD
1 year ago
Nov 20, 2023
Sell 32.9 K USD
McKelligon Brian
President and CEO
- 7500
4.3868 USD
1 year ago
Sep 07, 2023
Bought 32.2 K USD
Pla Frederic
Chief Operating Officer
+ 7000
4.6 USD
1 year ago
Sep 07, 2023
Bought 59.8 K USD
Pla Frederic
Chief Operating Officer
+ 13000
4.6011 USD
1 year ago
Jun 12, 2023
Bought 100 K USD
Ek John Frederick
CFO
+ 20000
5 USD
1 year ago
Jun 12, 2023
Bought 100 K USD
LAI GOLDMAN MYLA
Director
+ 20000
5 USD
1 year ago
Jun 12, 2023
Bought 100 K USD
Mendel Scott
Director
+ 20000
5 USD
1 year ago
Jun 12, 2023
Bought 1.02 M USD
Winkler Matthew
Director
+ 203388
5 USD
1 year ago
Jun 12, 2023
Bought 600 K USD
SHEPLER ROBERT G
Director
+ 120000
5 USD
1 year ago
Jun 12, 2023
Bought 9.02 M USD
Raffin Thomas A.
Director
+ 1803373
5 USD
1 year ago
Jun 12, 2023
Bought 983 K USD
Raffin Thomas A.
Director
+ 196627
5 USD
1 year ago
Jun 12, 2023
Bought 100 K USD
Raffin Thomas A.
Director
+ 20000
5 USD
1 year ago
Jun 06, 2023
Sell 28.5 K USD
McKelligon Brian
President/CEO
- 5000
5.7074 USD
2 years ago
Dec 13, 2022
Sell 1.32 K USD
Nolan Garry Ph.D.
Director
- 100
13.25 USD
1 year ago
Mar 14, 2023
Sell 43.6 K USD
McKelligon Brian
President/CEO
- 4774
9.135 USD
1 year ago
Mar 14, 2023
Sell 2.24 K USD
McKelligon Brian
President/CEO
- 226
9.918 USD
2 years ago
Dec 13, 2022
Sell 926 K USD
SCHNETTLER THOMAS P
Director
- 71050
13.03 USD
2 years ago
Dec 14, 2022
Sell 182 K USD
DRISCOLL JOSEPH
Chief Financial Officer
- 14574
12.455 USD
3 years ago
Dec 13, 2021
Sell 1.32 K USD
Nolan Garry Ph.D.
Director
- 100
13.25 USD
2 years ago
Dec 06, 2022
Sell 60.4 K USD
McKelligon Brian
President/CEO
- 5000
12.083 USD
2 years ago
Dec 02, 2022
Sell 14.6 K USD
Nolan Garry Ph.D.
Director
- 1100
13.25 USD
2 years ago
Dec 01, 2022
Sell 66.8 K USD
Nolan Garry Ph.D.
Director
- 5000
13.3576 USD
2 years ago
Nov 16, 2022
Sell 3.98 K USD
Nolan Garry Ph.D.
Director
- 300
13.2533 USD
2 years ago
Nov 10, 2022
Sell 50.7 K USD
Nolan Garry Ph.D.
Director
- 3810
13.3085 USD
2 years ago
Nov 11, 2022
Sell 266 K USD
Nolan Garry Ph.D.
Director
- 20000
13.2929 USD
2 years ago
Nov 14, 2022
Sell 7.97 K USD
Nolan Garry Ph.D.
Director
- 600
13.2767 USD
2 years ago
Sep 14, 2022
Sell 110 K USD
Nolan Garry Ph.D.
Director
- 8305
13.2552 USD
2 years ago
Sep 09, 2022
Sell 295 K USD
Nolan Garry Ph.D.
Director
- 22191
13.3089 USD
2 years ago
Sep 12, 2022
Sell 23.9 K USD
Nolan Garry Ph.D.
Director
- 1800
13.3023 USD
2 years ago
Sep 07, 2022
Sell 64.2 K USD
McKelligon Brian
President/CEO
- 5000
12.834 USD
2 years ago
Jun 15, 2022
Sell 51.3 K USD
McKelligon Brian
President/CEO
- 5000
10.252 USD
3 years ago
Dec 09, 2021
Sell 317 K USD
Nolan Garry Ph.D.
Director
- 25000
12.6705 USD
3 years ago
Nov 22, 2021
Bought 328 K USD
Ramachandran Niro Ph.D
Chief Business Officer
+ 25000
13.1317 USD
3 years ago
Nov 19, 2021
Bought 938 USD
Ramachandran Niro Ph.D
Chief Business Officer
+ 73
12.85 USD
3 years ago
Nov 19, 2021
Bought 112 K USD
Mendel Scott
Director
+ 8500
13.16 USD
3 years ago
Nov 18, 2021
Bought 258 K USD
SHEPLER ROBERT G
Director
+ 20000
12.925 USD
3 years ago
Nov 18, 2021
Bought 183 K USD
SHEPLER ROBERT G
Director
+ 15000
12.167 USD
7. News
Kent Lake Issues Letter to Quanterix Shareholders Regarding Opposition to the Company's Proposed Merger with Akoya Biosciences RINCON, Puerto Rico--(BUSINESS WIRE)--Kent Lake PR LLC (“Kent Lake”), a holder of 5.9% of the outstanding common stock of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), today highlighted its opposition to the Company's proposed merger (the “Merger”) with Akoya Biosciences (“Akoya”) (NASDAQ: AKYA). Kent Lake has also issued an open letter to all Quanterix shareholders outlining how the Merger significantly undervalues the Company and its intention to take all necessary step. businesswire.com - 1 week ago
Akoya Biosciences Unveils Strategic Product Roadmap, Powered by the New IO60 and Upcoming Neurobiology Panels Rapid menu expansion with new high-plex human and mouse neurobiology panels joining the recently launched Human IO60 and Mouse FFPE IO Panels globenewswire.com - 3 weeks ago
Akoya Biosciences Selects Argonaut Manufacturing Services as IVD Manufacturing Partner CARLSBAD, Calif.--(BUSINESS WIRE)--Argonaut Manufacturing Services (“Argonaut”), a leading contract development and manufacturing organization serving the biopharma and life sciences industries, and Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, announced today that Argonaut will act as the manufacturing partner for Akoya's IVD assays currently in development. This agreement builds on years of collaboration between Argonaut and Akoya, reflecting Argonaut's prove. businesswire.com - 1 month ago
Quanterix price target lowered by $4 at TD Cowen, here's why Quanterix + Akoya Biosciences +0.39 (+14.72%) https://thefly.com - 1 month ago
AKOYA BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc. - AKYA NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Akoya Biosciences, Inc. (NasdaqGS: AKYA) to Quanterix Corporation (NasdaqGM: QTRX). Under the terms of the proposed transaction, shareholders of Akoya will receive 0.318 shares of Quanterix for each share of Akoya that they own. KSF is seeking to determine whether this consideration and the process that led to. businesswire.com - 1 month ago
Shareholder Alert: Ademi LLP Investigates Whether Akoya Biosciences, Inc. Is Obtaining a Fair Price for Its Public Shareholders MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Akoya (NASDAQ: AKYA) for possible breaches of fiduciary duty and other violations of law in its transaction with Quanterix. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, Akoya stockholders will receive only 0.318 shares of Quanterix common stock for each share of Akoya common stock. businesswire.com - 1 month ago
AKYA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Akoya Biosciences, Inc. Is Fair to Shareholders NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Akoya Biosciences, Inc. (NASDAQ: AKYA) to Quanterix Corporation for 0.318 shares of Quanterix common stock for each share of Akoya common stock is fair to Akoya shareholders. Halper Sadeh encourages Akoya shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersad. businesswire.com - 1 month ago
Quanterix to Acquire Akoya Biosciences, Creating the First Integrated Solution for Ultra-Sensitive Detection of Blood- and Tissue-Based Protein Biomarkers BILLERICA, Mass. and MARLBOROUGH, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, and Akoya Biosciences (NASDAQ: AKYA), The Spatial Biology Company®, today announced a definitive merger agreement under which Quanterix will acquire Akoya in an all-stock transaction. The transaction will create the first integrated solution for ultra-sensitive detection of blood- and tissue-based protein biomarkers. businesswire.com - 1 month ago
Akoya Biosciences and NeraCare Enter into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment Decisions Akoya expands clinical test menu, exclusively licensing the global rights to develop and commercialize NeraCare's Immunoprint test for prognostication of disease recurrence in early-stage melanoma patients to better guide treatment decisions and potentially increase access to life saving therapies for those patients at high risk of developing metastatic disease Akoya expands clinical test menu, exclusively licensing the global rights to develop and commercialize NeraCare's Immunoprint test for prognostication of disease recurrence in early-stage melanoma patients to better guide treatment decisions and potentially increase access to life saving therapies for those patients at high risk of developing metastatic disease globenewswire.com - 2 months ago
Akoya Biosciences, Inc. (AKYA) Q3 2024 Earnings Call Transcript Akoya Biosciences, Inc. (NASDAQ:AKYA ) Q3 2024 Earnings Conference Call November 14, 2024 5:00 PM ET Company Participants Priyam Shah - Head, IR Brian McKelligon - CEO Johnny Ek - CFO Conference Call Participants William Bonello - Craig-Hallum Mason Carrico - Stephens Kyle Mikson - Canaccord David Westenberg - Piper Tejas Savant - Morgan Stanley Subbu Nambi - Guggenheim Securities Mark Massaro - BTIG Operator Hello and thank you for standing by. Welcome to the Akoya Biosciences Third Quarter 2024 Earnings Conference Call. seekingalpha.com - 3 months ago
Akoya Biosciences (AKYA) Reports Q3 Loss, Lags Revenue Estimates Akoya Biosciences (AKYA) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.26 per share a year ago. zacks.com - 3 months ago
Akoya Biosciences Reports Third Quarter 2024 Financial Results MARLBOROUGH, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the third quarter ending September 30, 2024. globenewswire.com - 3 months ago
8. Profile Summary

Akoya Biosciences, Inc. AKYA

image
COUNTRY US
INDUSTRY Medical - Instruments & Supplies
MARKET CAP $ 80.8 M
Dividend Yield 0.00%
Description Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers Proxima, a cloud-based platform to store, analyze, and share spatial data; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.
Contact 100 Campus Drive, Marlborough, MA, 01752 https://www.akoyabio.com
IPO Date April 16, 2021
Employees 330
Officers Mr. Priyam Shah Senior Director of Business Development & Investor Relations Strategy Ms. Jennifer Kamocsay Chief Legal Officer Mr. Brian McKelligon President, Chief Executive Officer & Director Mr. John Frederick Ek CPA Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer Mr. Anthony Catalano Senior Vice President of Operations Dr. Niro Ramachandran Ph.D. Chief Business Officer Dr. Pascal Bamford Ph.D. Senior Vice President of Research & Development and Laboratory Operations Mr. Rob C. Hart CFA, J.D. Secretary